Earnings update: Vontier, AvidXchange, Fennec, G1 Therapeutics, Enact, Verona
A flood of quarterly earnings for North Carolina public companies continues with Vontier, AvidXchange, Fennec, G1 Therapeutics, Enact, Verona reporting.
Read More
G1 Therapeutics
Earnings: United Therapeutics, AvidXchange, G1 Therapeutics, Enact report financials
United Therapeutics, AvidXchange, G1 Therapeutics and Enact are the latest publicly traded companies with headquarters or major operations in North Carolina to report quarterly financials.
Read More
Durham-based G1 Therapeutics discontinues colorectal cancer drug trial
G1 Therapeutics,which is focused on oncology research, will no longer seek to explore one of its drug candidates as a treatment for colorectal cancer, the company announced Monday.
Read More
Triangle oncology firm G1 Therapeutics raises $50M with millions more possible
G1 Therapeutics is rolling out clinical trials for possible drugs such as one targeting colorectal cancer, and to fund that surge the company has raised some $50 million. Millions more may be on the way.
Read More
Durham cancer therapy firm G1 to expand sales force, ends co-promotion deal
G1 Therapeutics is expanding its own sales force to handle its recently FDA approved cancer treatment. Here’s what’s happening.
Read More
After 13 years of trials and tribulations RTP firm G1 wins first FDA approval for cancer drug
After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration.
Read More
RTP drug firm G1 secures FDA approval for treatment to prevent chemo damage to bone marrow
Patients undergoing treatment for lung cancer will soon have access to a treatment that prevents damage to their bones and immune system from chemotherapy that has won FDA approval for Triangle-based G1 Therapeutics.
Read More
G1 Therapeutics names former GSK exec as its next CEO
John Bailey, a veteran pharmaceutical industry executive, will take over as CEO effective Jan. 1 at G1 Therapeutics as part of a leadership transition plan, the RTP-based firm says.
Read More
Triangle’s G1 Therapeutics reaches key milestone in fight against cancer
G1 Therapeutics, a clinical-stage oncology company based in Research Triangle Park, has reached an important regulatory milestone for its potential therapy for small cell lung cancer. We’ve got the details.
Read More
